BD, a leading global medical technology company, announced additional investments in its US manufacturing facility to add capacity for critical medical devices, including syringes, needles and IV catheters.

BD expands its manufacturing of critical medical devices in US. (Source: BD)

In 2024, the company invested more than US$10 million to expand manufacturing capacity with new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska.

One line is already fully operational with additional lines expected to start up in the coming months. These new lines will boost BD’s capacity of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by more than 50%.

In addition, BD also plans for investing more than US$30 million in 2025 to expand manufacturing capacity for IV lines at its plant in Utah to support continued growth in catheter solutions.

This follows BD’s investment in 2024 of more than US$2 million for IV line improvements that resulted in increased IV catheter output by more than 40 million units annually.

“By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also are reinforcing our commitment to the nation's health care infrastructure,” said Eric Borin, president of Medication Delivery Solutions at BD.

BD, a leading global medical technology company, announced additional investments in its US manufacturing facility to add capacity for critical medical devices, including syringes, needles and IV catheters.

BD expands its manufacturing of critical medical devices in US. (Source: BD)

In 2024, the company invested more than US$10 million to expand manufacturing capacity with new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska.

One line is already fully operational with additional lines expected to start up in the coming months. These new lines will boost BD’s capacity of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by more than 50%.

In addition, BD also plans for investing more than US$30 million in 2025 to expand manufacturing capacity for IV lines at its plant in Utah to support continued growth in catheter solutions.

This follows BD’s investment in 2024 of more than US$2 million for IV line improvements that resulted in increased IV catheter output by more than 40 million units annually.

“By expanding our production capacity, we are not only meeting the critical needs of patients and providers, but we also are reinforcing our commitment to the nation's health care infrastructure,” said Eric Borin, president of Medication Delivery Solutions at BD.